Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Atenolol
Drug ID BADD_D00178
Description Atenolol is a cardioselective beta-blocker used in a variety of cardiovascular conditions. Sir James Black, a Scottish pharmacologist, pioneered the use of beta-blockers for the management of angina pectoris in 1958 for which he received the Nobel Prize.[A178429] Beta-blockers quickly became popular in clinical use and where subsequently investigated for use in myocardial infarction, arrhythmias, and hypertension during the 1960s. Later they continued to be investigated for use in heart failure throughout the 1970-1980s. Atenolol itself was developed early on in this history by Alvogen Malta under the trade name Tenormin and received FDA approval in September, 1981.[label] Despite being one of the most widely prescribed beta blockers, evidence suggests atenolol may not significantly reduce mortality, and only modestly reduce the risk of cardiovascular disease in patients with hypertension.[A235850,A235855] A Cochrane review of patients being treated for primary hypertension shows that atenolol shows a risk ratio of 0.88 for cardiovascular disease risk and a risk ratio of 0.99 for mortality.[A235850,A235855] Similar results have been found in other meta-analyses.[A235860,A235865] A meta-analysis of over 145,000 patients showed the risk of stroke in patients taking atenolol may depend on the age of the patient.[A235865] The use of atenolol may need to be based on more patient factors than hypertension alone.[A235850,A235855,A235860,A235865]
Indications and Usage For the management of hypertention and long-term management of patients with angina pectoris
Marketing Status Prescription; Discontinued
ATC Code C07AB03
DrugBank ID DB00335
KEGG ID D00235
MeSH ID D001262
PubChem ID 2249
TTD Drug ID D01UXC
NDC Product Code 60760-787; 50090-2923; 67296-1589; 70934-142; 65862-169; 53002-2138; 68071-4274; 50090-5741; 50090-5363; 50090-3411; 68788-7784; 68788-7528; 52427-429; 0378-0231; 71335-1108; 51079-685; 48589-0007; 0904-7187; 0615-8026; 65841-024; 70518-0379; 65862-168; 65841-022; 70518-3036; 63187-710; 61919-914; 71335-0954; 55700-754; 68788-7535; 60429-027; 68071-4538; 53002-4108; 70934-537; 68382-022; 65862-170; 70518-0399; 71335-0988; 68788-7616; 67296-1270; 55700-755; 63187-092; 52427-430; 51079-684; 52427-431; 61919-854; 50090-5266; 60760-163; 67544-161; 70934-457; 64980-437; 60760-164; 43063-765; 68382-023; 71205-496; 67296-1288; 60687-605; 68071-4751; 68071-4526; 70518-0351; 70934-219; 67296-1726; 70518-2866; 60429-025; 65841-023; 29300-410; 60429-026; 71335-0912; 70518-2939; 0093-0787; 63629-2626; 0093-0753; 0615-8027; 68071-2248; 51604-0012; 67296-1201; 53002-1138; 0378-0757; 50090-0442; 71335-0540; 68071-1772; 60760-643; 70518-0882; 68071-4766; 70934-458; 68071-1771; 68382-024; 55154-5455; 12660-0007; 51079-759; 68071-4527; 42708-012; 0378-0218; 43353-986; 71335-0668; 61294-9994; 71335-1535; 43063-952; 63629-1785; 71205-229; 72189-135; 50090-3410; 72189-152; 68071-4553; 60760-437; 68788-7876; 63187-537; 67544-240; 57451-1115; 38779-0262; 64980-438; 68645-585; 0615-8373; 61919-664; 71335-1264; 50090-5738; 53002-1004; 51927-2467; 42185-7034; 29300-411; 67296-1732; 68071-5162; 50090-5233; 64980-439; 43063-805; 63187-201; 72189-146; 68071-5033; 67544-332; 70934-177; 0615-8372; 0093-0752; 71335-1616; 53002-2004; 29300-412; 61919-581; 63629-8029; 42708-143; 67296-1558; 60760-642; 60760-256; 43353-834; 50090-5408; 50090-3043; 61919-257; 65841-101; 70518-3007; 53002-1108; 70934-463; 49452-0020; 55154-5511; 72789-144; 71205-096; 61919-279; 50090-5367; 51927-0208
Synonyms Atenolol | Tenormine | Tenormin | ICI-66082 | ICI 66082 | ICI66082
Chemical Information
Molecular Formula C14H22N2O3
CAS Registry Number 29122-68-7
SMILES CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood sodium decreased13.11.01.0120.000074%Not Available
Body temperature increased13.15.01.001--Not Available
Bone disorder15.02.04.0040.000074%Not Available
Bone pain15.02.01.001--
Bradycardia02.03.02.0020.007058%Not Available
Bronchitis11.01.09.001; 22.07.01.0010.000148%
Bronchospasm10.01.03.012; 22.03.01.0040.000148%
Bundle branch block left02.03.01.0070.000148%Not Available
Burning sensation08.01.09.029; 17.02.06.001--Not Available
Cardiac arrest02.03.04.0010.000193%
Cardiac failure02.05.01.0010.000096%
Cardiac failure congestive02.05.01.002--Not Available
Cardio-respiratory arrest02.03.04.002; 22.02.06.0070.000135%Not Available
Cardiogenic shock02.05.01.003; 24.06.02.0060.000628%Not Available
Cardiomegaly02.04.02.0010.000019%Not Available
Carotid artery stenosis17.08.02.001; 24.04.06.0010.000074%Not Available
Carpal tunnel syndrome17.09.02.0010.000074%Not Available
Cataract06.06.01.0010.000148%
Catatonia19.11.01.001--Not Available
Cerebellar syndrome17.02.02.0020.000074%Not Available
Cerebral haemorrhage17.08.01.003; 24.07.04.0010.000048%Not Available
Cerebral ischaemia17.08.01.005; 24.04.06.0030.000148%
Cerebrovascular accident17.08.01.007; 24.03.05.001--
Chest discomfort02.02.02.009; 08.01.08.019; 22.02.08.0010.000333%Not Available
Chest pain02.02.02.011; 08.01.08.002; 22.02.08.0030.000628%Not Available
Chills08.01.09.001; 15.05.03.0160.000222%
Cholelithiasis09.03.01.0020.000074%Not Available
Cholestasis09.01.01.0010.000148%Not Available
Circulatory collapse24.06.02.0010.000111%Not Available
Cleft lip and palate03.04.02.003; 07.05.08.0030.000259%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 17 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene